The Drugs Controller General of India (DCGI) has given nod for using cancer treatment drug repurposed for Covid-19 treatment– 2-deoxy-D-glucose (2-DG) for emergency use as an adjunct therapy for hospitalized moderate to severe Covid-19 patients.The anti-Covid-19 therapeutic application of the drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a Defence Research and Development Organisation (DRDO) lab, in collaboration with pharma major Dr Reddy’s Laboratories, The Statesman reported.
The drug, which comes in a sachet in powder form has to be taken orally by dissolving it in water. The drug works by accumulating in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production.
“Its selective accumulation in virally infected cells makes this drug unique. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid-19 patients,” INMAS-DRDO said.
Based on phase II results, DCGI further permitted the Phase-III clinical trials in November 2020 which was studied over 220 subjects taken from 27 hospitals across the country.